ChemoCentryx Inc (CCXI), GlaxoSmithKline plc (ADR) (GSK): Horrendous Health-Care Stocks This Week

Page 2 of 2

Staying horrendous
I suspect that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will make a nice rebound from this week’s decline. Prosensa Holding NV (NASDAQ:RNA) also has at least a decent shot at making a comeback. Any good news from the phase 3 study of drisapersen or any bad news for Sarepta Therapeutics Inc (NASDAQ:SRPT) will help the stock.

Recovery for ChemoCentryx Inc (NASDAQ:CCXI) could be much more difficult, though. It wouldn’t be the end of the road for the biotech if GlaxoSmithKline plc (ADR) (NYSE:GSK)’s review of the vercirirnon data leads to a cancellation of development of the drug. However, it would be a huge and damaging detour. That worst-case scenario might not happen, but I think ChemoCentryx is the most likely of this week’s horrendous health-care stocks to stay on the “horrendous” list.

The article 3 Horrendous Health-Care Stocks This Week originally appeared on Fool.com.

Fool contributor Keith Speights and The Motley Fool have no position in any of the stocks mentioned. 

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2